Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 6/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8800403 | 0.83 | CTSB (0.62) | CYP2A13CYP2C9ALOX15HSD17B10CYP3A4 | |
| SCHEMBL3175715 | 0.81 | CYP2A13 (0.67) | CYP2A13CYP2C9ALOX15HSD17B10ALDH1A1 | |
| SCHEMBL16028316 | 0.81 | CYP2A13 (0.61) | CYP2A13CYP2C9ALOX15HSD17B10CYP3A4 | |
| SCHEMBL10398153 | 0.80 | CYP2C9 (0.66) | CYP2A13CYP2C9ALOX15HSD17B10CYP3A4 | |
| SCHEMBL872020 | 0.79 | CYP2C9 (0.56) | CYP2A13CYP2C9ALOX15HSD17B10CYP3A4 | |
| Water SCHEMBL27791264 | 0.79 | CYP2C9 (0.56) | CYP2A13CYP2C9ALOX15HSD17B10CYP3A4 | |
| SCHEMBL4909115 | 0.79 | CYP2A13 (0.55) | CYP2A13CYP2C9ALOX15HSD17B10CYP3A4 | |
| SCHEMBL23235219 | 0.77 | CYP2C9 (0.62) | CYP2A13CYP2C9ALOX15HSD17B10CYP3A4 | |
| SCHEMBL30830470 | 0.77 | CYP2C9 (0.62) | CYP2A13CYP2C9ALOX15HSD17B10CYP3A4 | |
| SCHEMBL15915825 | 0.77 | CYP2A13 (0.56) | CYP2A13CYP2C9ALOX15HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2778156-B1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | ASTRAZENECA AB (SE) | 2016-11-30 | — | — | EP | disclosed |
| EP-2106396-B1 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ALCON RES LTD (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2778156-A1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | AstraZeneca AB (Publ) (SE) | 2014-09-17 | — | — | EP | disclosed |
| US-8273774-B2 | Phenoxypyridinylamide compounds | ASTRAZENECA AB (SE) | 2012-09-25 | — | — | US | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| US-20100041638-A1 | Chemical Compounds 293 | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| EP-2106396-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | AstraZeneca AB (SE) | 2009-10-07 | — | — | EP | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| WO-2008084223-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | CYP2A13 310/4885CYP2C9 835/4885ALOX15 1947/4885 |
| US-20100041638-A1 | Chemical Compounds 293 | PDE4B, PDE4A, PDE3B | CYP2A13 369/4885CYP2C9 175/4885ALOX15 2847/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | CYP2A13 310/4885CYP2C9 835/4885ALOX15 1947/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | CYP2A13 580/4885CYP2C9 688/4885ALOX15 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.